 |
|
Multiple Sclerosis
Therapeutic Update
Alexandros C. Tselis, MD, PhD;
Robert P. Lisak, MD
Arch Neurol. 1999;56:277-280.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Therapy for multiple sclerosis (MS) is undergoing rapid changes. We discuss recent developments in the therapy of MS, failures as well as successes, and consider some newer approaches. Multiple sclerosis, a multifocal, initially remitting-relapsing, and in some cases primarily progressive, inflammatory central nervous system immune-mediated demyelinating disease, with some axonal involvement, is currently the most common disabling neurologic disease of young people in North America and Europe. Although much is known about the pathogenesis, there is no cure and the disease must be managed long-term. Recently, there have been a number of advances in the treatment of MS.
There are several dimensions to the therapy of MS: treatment of the underlying disease (treatment of relapses, prevention or modulation of relapses, and prevention of progression) and treatment of the effects of the disease (treatment of symptoms and provision of support). Since there . . . [Full Text of this Article]
PREVENTION OF RELAPSES AND ACCUMULATION OF DEFICIT
INTERFERONS
GLATIRAMER ACETATE (FORMERLY COPOLYMER-1)
OTHER AGENTS
TREATMENT OF RELAPSES
ORAL CORTICOSTEROIDS
SUMMARY AND FUTURE DIRECTIONS
From the Department of Neurology, Division of Neuroimmunology, Wayne State University School of Medicine, Detroit Medical Center, Detroit, Mich.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(3):370-371.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A gene therapy approach for treating T-cell-mediated autoimmune diseases
Chen et al.
Blood 2001;97:886-894.
ABSTRACT
| FULL TEXT
Progress in MS Therapy Trials
JWatch Neurology 1999;1999:13-13.
FULL TEXT
|
